example, the way CsA is used either alone or in combination with MTX varies considerably from centre to centre.
760 Table 1 Centres which sent a report, by country h in two centres, 6-8 h in four centres, and 12-13 h in six centres.
Australia 2
The median initial daily dose of intravenous CsA was 3 Austria 1 mg/kg, the range was 1-20 mg/kg. Four centres gave the Belgium 5 dose of 1 mg/kg, seven centres 8 mg/kg or more. Croatia 1 The intravenous administration was changed to the oral Czech Republic 1 Denmark 1 route at a median of day 21 (range 7-40). Fifteen centres Finland 2 initiated oral administration at 2 weeks or earlier, 12 centres France 5 at 4 weeks or later after the transplantation. When a predeGermany 6 fined initial oral dose was given, this was between 2 and Greece 4
12.5 mg/kg/day, median 10 mg/kg/day. Seven centres gave The most common duration of CsA prophylaxis after Slovakia 1 transplantation was 6 months (54 centres). Thirteen centres Slovenia 1 gave CsA for 100-150 days and 12 centres for 1 year. Four
South Africa 1 Spain 6
centres discontinued the administration before day 100.
Sweden 4
Four centres reported different durations of treatment Switzerland 2 according to patient group. Turkey 5 When CsA was discontinued, the administration was United Kingdom 14 USA 1 stopped abruptly in 10 centres. All the other centres tapered the dose. After switching to oral administration, the CsA doses were principally determined according to blood concentrations in 63 centres. In 10 centres a fixed cyclosporine Results dose was given in principle, and in 11 centres the dose was gradually tapered according to a predefined protocol. In the Prophylaxis of acute GVHD two latter policies, most centres reported guidelines to modify the fixed dose in cases of toxicity or excessively high Of the 87 centres, 81 (93%) used the combination of CsA and a short course of MTX for all or some groups of blood concentrations. CsA concentrations were measured from whole blood in patients. CsA alone was given to at least some patient groups by 17 (20%) centres and MTX alone by two centres.
69 centres and from serum in 12 centres. Sixty-five centres reported the method of CsA concentration determination. T cell depletion was in use in 20 (23%) centres. Other forms of prophylaxis, used either for all or some subgroups Forty-one used Abbott FPIA (Abbott Laboratories, Abbott Park, IL, USA), 18 CYCLO-Trac RIA (Incstar Corporation, of patients, were reported by 25 centres. These other forms of prophylaxis were most often combinations of the aboveStillwater, MN, USA), three Syva Emit (Syva Company, San Jose, CA, USA), and three other methods. mentioned modalities and corticosteroids. Figure 1 shows the distribution of target CsA blood concentrations at 2-3 months after transplantation. The concenCyclosporine A: With one exception, all centres using both the combination of CsA and MTX, and CsA alone reported trations most widely accepted were 250-400 g/l. Most of the target ranges were between 100 and 500 g/l, but some using CsA according to the same schedule in both instances. There was only one centre in which prophylaxis centres aimed at concentrations of up to 800 g/l and one with CsA alone was in use and in which no group of patients received CsA + MTX. For the purposes of the present analysis, the practices of using CsA were analyzed irrespective of whether the drug was used in combination with MTX or alone.
The administration of CsA was initiated on day −1 in relation to the transplant in 79 of 86 centres. In one centre the administration started on day −2, in four centres on day −3, in one on day −4 and in one to a subgroup of patients on day −7. The drug was given intravenously in all but two centres, in which it was given orally. Thirty-two centres gave CsA as continuous intravenous infusion, 51 centres as infusion was given, the duration of the infusion was 2-4 centre up to 1000 g/l. In 15 centres the highest accepted dose was 2-2.5 mg/kg/day; this dose was given in 39 centres. Twenty-nine centres gave 7 mg/kg/day or more, blood concentration was 200 g/l or less, in 19 centres 400 g/l or more. In seven centres the lower limit of the theraand 17 centres 15 mg/kg/day or more. The lowest initial dose was 0.5 and highest 45 mg/kg/day. The daily dose peutic range was 300 g/l or more.
Twenty-six centres used CsA capsules, 25 gave a soluble was given in one dose in 24 centres, and in two divided doses in 38 centres, in three doses in 13 centres, and in preparation, and 34 centres used both.
four doses in four centres. The severity of acute GVHD at presentation was reported MTX in combination with CsA: In the combination of CsA and short course MTX, the majority (55 centres) gave four to affect the initial corticosteroid dose in 36 centres whereas it had no effect in 50 centres. The severity of acute GVHD doses of MTX according to the original Seattle protocol: 15 mg/m 2 on day +1, and 10 mg/m 2 on days +3, +6, and at presentation was more likely to affect the initial dose in the centres which used a low routine initial dose, but there +11. The same schedule without the day 11 dose was used by 15 centres. Eleven centres had slightly different schedwere 15 centres which reported only treating grade II or more GVHD, using a routine initial dose of 1 to 2 ules. In most cases the doses were a little smaller, 8-10 mg/m 2 in the first dose and 6-8 mg/m 2 in the following mg/kg/day, and not taking into account the severity of GVHD when determining the initial dose. doses, but in one instance 12 mg/m 2 was given in each of four doses. The timing was also slightly different in some Thirty-two centres had a schedule of tapering the initial corticosteroid dose. The majority, 53 centres, reported modcentres, the days of administration being days +2, +4, +8 (and +12).
ifying the initial dose on an individual basis. Two centres discontinued CsA at the time of the Folinic acid rescue was given after the MTX administration in 37 centres. Forty-four centres did not use folinic initiation of corticosteroid treatment for acute GVHD. All the other centres continued CsA administration (at any acid rescue. In 24 centres the folinic acid dose was the same as the preceding MTX dose. In the remaining 11 centres, dose). The centres were asked to report the dose of corticothe dose varied greatly ranging from a total dose of 3 mg to 15 mg/kg. The schedule of folinic acid rescue also steroid and unresponsiveness, which was regarded as indicating corticosteroid-resistant GVHD and to be an indivaried. The time from MTX administration to the first administration of folinic acid was 4 h in one centre, 6 h in cation for second-line treatment. Responses are shown in Table 3 . The definitions varied greatly. Nineteen centres three centres, 12 h in 10 centres, 24 h in 21 centres, 36 h in one centre and 48 h in one centre. In almost all centres regarded unresponsiveness to 1-2 mg/kg/day of methylprednisolone (or equivalent) to indicate corticosteroid resistat least part of the folinic acid dose was given intravenously; two centres gave the whole rescue by mouth.
ance whereas in 14 centres this dose was 20 mg/kg/day or more. The lowest dose indicating corticosteroid resistance was 1 mg/kg/day and the highest 40 mg/kg/day.
Treatment of acute GVHD
Second-line treatment was ATG or ALG in 51 centres, monoclonal antibodies in 23 centres, high doses of corticoAll centres used corticosteroids as first line treatment. Seventy-six centres used methylprednisolone, eight prednisosteroids in 12 centres, azathioprine in four centres, and thalidomide in three centres (several centres had alternatives). lone, and three prednisone. The treatment was initiated at the first signs likely to be caused by acute GVHD The most commonly used monoclonal antibodies were OKT3 and IL-2 receptor antibodies (seven centres each), (including grade I) in 30 centres, whereas 54 centres only treated GVHD of grade II or more. The decision to treat and CAMPATH 1G (five centres). acute GVHD was based on clinical findings solely in 71 centres, whereas in 14 centres histological evidence of acute GVHD was required. The treatment was given intraDiscussion venously in 76 centres and orally in 13 centres (two centres had alternatives).
The results of this survey are likely to reflect the practices of the prophylaxis and treatment of acute GVHD in Europe The initial routine corticosteroid dose is shown in Table  2 . If a fixed dose was reported, the mg/kg dose was calcurelatively well, as information was received from 87 centres which represents approximately half of the allogeneic BMT lated for an average sized adult. The most commonly used Table 2 Initial corticosteroid dose (methylprednisolone or equivalent) for the treatment of acute GVHD centres in Europe. Geographic coverage was also good as for less than 150 days is associated with a higher rate of chronic GVHD than longer prophylaxis. 2 A non-ranshown in Table 1 .
The survey was principally designed to ascertain the domized study by Schwinghammer et al 3 suggested that 5 mg/kg/day at the early stage after BMT is more effective practical details of GVHD prophylaxis with immunosuppressive agents, CsA and MTX in particular, as well as in the prevention of acute GVHD than 3 mg/kg/day. Many aspects of CsA prophylaxis remain unclear. the policy of treating acute GVHD. No effort was made to evaluate in detail the forms of prophylaxis used for speci-
The findings of this survey concerning the use of folinic acid rescue are interesting. In publications of patients fied groups of patients. Therefore, this study gives only an approximate idea of the extent to which different forms of receiving CsA + short MTX, the use of folinic acid rescue is rarely mentioned. However, almost half of the centres prophylaxis are used. However, it is clear that the combination of CsA with a short course of MTX is the most give folinic acid. This may be of clinical importance. It has clearly been shown that the addition of methotrexate to widely used form of prophylaxis. This was used by 81 of the 87 centres for at least some groups of patients. CsA cyclosporine prophylaxis delays recovery of bone marrow function and may increase gastrointestinal and liver toxalone was in use in 17 centres, but in only two centres was there a protocol consisting of methotrexate only for any icity. 4, 5 Modifying the effect of MTX with folinic acid may have impact on the effects of GVHD prophylaxis. type of patients. Twenty centres reported using T cell depletion. This is likely to be an underestimate of the real Another finding of interest was the way corticosteroid resistance was defined. The methylprednisolone (or situation, as this survey did not focus on the details of this procedure and many centres using T cell depletion probably equivalent) dose, resistance to which was regarded as indicating corticosteroid resistance, varied from 1 to 40 did not respond for this reason. Although the well known risks of T cell depletion including increased risk of graft mg/kg/day. In 12 centres the second-line treatment for corticosteroid-resistant patients was more corticosteroids. It failure and relapse became apparent in the late 1980s and at least temporarily reduced enthusiasm for this form of is obvious that there is no general agreement on the definition on corticosteroid resistance, and the term is used in prophylaxis, a considerable proportion of allogeneic BMT centres continue to use T cell depletion today.
greatly variable ways. The information obtained from this kind of survey may The main message of this survey is the considerable variability in the practical details of superficially similar be useful to individual transplant centres. The practices are generally known to vary, but it is difficult to know what protocols used for the prophylaxis and treatment of acute GVHD. For example the most widely used prophylaxis, exactly is done in other centres. An improved knowledge of what others do may help to critically review one's own CsA together with a short course of MTX, varied widely in administration details. The dosage of CsA and target practices. It is not possible to define an optimum practice. However, for a new centre it may be sensible to apply the therapeutic blood concentrations were markedly different in different centres. The reported CsA blood concentrations most widely used practice. Some central features of the 'average' protocol can be delineated as follows: were not directly comparable as different assay methods were used, but this can only account for a small part of the GVHD prophylaxis is initiated on day −1 with CsA 3 mg/kg/day intravenously divided into two daily doses. The variability in target concentrations. The doses were determined in the majority of centres according to blood concenadministration is switched to the oral route in the absence of gastrointestinal complications at 3 weeks after transplantrations, but a number of centres used fixed dose schedules. The routine duration of CsA prophylaxis ranged from less tation, and the initial oral dose is 10 mg/kg/day divided into two doses. Subsequent doses are determined according to than 100 days up to 1 year. The administration of MTX in combination with CsA was relatively uniform, but almost blood levels, the target trough concentrations being 250-400 g/l at 2-3 months. CsA prophylaxis is continued for half the centres gave folinic acid rescue after MTX, whereas the other half did not. All centres used cortico-6 months, and the dose is tapered at discontinuation. MTX is given intravenously at a dose of 15 mg/m 2 on day +1 steroids as first-line treatment for acute GVHD, but the aggressiveness of treatment varied greatly. One third of the and 10 mg/m 2 on days +3, +6 and +11. Folinic acid is not routinely given. Acute GVHD is initially treated with centres initiated treatment at the first clinical signs likely to be caused by acute GVHD, but the majority only treated methylprednisolone at a dose of 2 mg/kg/day intravenously, divided into two doses. GVHD of grade II or more is grade II or more. Most centres made the decision to treat on the basis of clinical findings only, but a number of treated. In cases of progression, the dose is increased to 10 mg/kg/day. Corticosteroid-resistant GVHD (resistance to centres needed histological evidence of GVHD before the decision to treat was made. The initial corticosteroid dose 10 mg/kg/day of methylprednisolone) is treated with ALG or ATG. However, it is clear that what most centres do is varied from 0.5 to 45 mg/kg/day. The most widely used initial dose was 2-2.5 mg/kg/day, but a large number of not necessarily the best alternative. Many of the routine practices are not based on solid scientific evidence. centres gave much higher doses, 7 mg/kg/day or more.
The optimum way to use CsA is not known, as also demThis survey demonstrates that important differences exist between the practices of giving GVHD prophylaxis or treatonstrated by this survey. Reports of properly controlled studies on this subject are few. Bacigalupo et al 1 showed ing GVHD despite superficially similar protocols. This has to be taken into account when interpreting the results of that 1 mg/kg/day during the first 3 weeks is associated with a higher incidence of acute GVHD but lower treatmentpublished reports on allogeneic BMT. It is likely that such differences have an impact on the results obtained. When related toxicity, lower relapse rate, and better survival than 5 mg/kg/day. They also showed that CsA prophylaxis planning new trials, these marked differences in practices 
